Clinical Trials Browser

Interventional × Breast Neoplasms × elacestrant × Clear all

NCT05386108 2026-02-05

ELECTRA

Phase 1/2 Recruiting

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT07222215 2026-01-22

CAPELA

Phase 2 Recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06691035 2025-12-04

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT07159451 2025-12-01

POP-ELA

Phase 2 Recruiting

Breast Neoplasms

NCT07242352 2025-11-21

ADAPTela

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

Phase 3 Recruiting

Breast Neoplasms

NCT05596409 2025-06-05

ELCIN

Phase 2 Active not recruiting

Breast Neoplasms

NCT05982093 2025-05-22

SOLTI-2104

Phase 2 Active not recruiting

Breast Neoplasms

NCT05618613 2025-05-09

ELONA

Phase 1/2 Terminated

Breast Neoplasms

NCT04791384 2023-07-27

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT04797728 2022-10-26

ELIPSE

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms